Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott

This article was originally published in The Gray Sheet

Executive Summary

Plans first quarter 1994 worldwide launch of its AxSym random, continuous and immediate access immunoassay analyzer and Maestro data management system, which allows "the integration of up to eight analyzers." Abbott announced development of AxSym in November 1992 ("The Gray Sheet" Nov. 16, 1992, p. 11). The two devices were previewed at an American Association for Clinical Chemistry meeting in New York. Shipments are to begin following FDA clearance of assays for the analyzer, which was okayed for marketing in 1992. The AxSym will list for about $124,000, and the Maestro will carry a price of "just over $38,000".

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000934

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel